The impact of polyunsaturated fatty acid-based dietary supplements on disease biomarkers in a metabolic syndrome/diabetes population

Lipids in Health and Disease

Floyd H Chilton³  Ethel O Kouba⁵  Timothy Morgan¹  Larry Douglas Case¹  Susan Sergeant⁴  Austin G Hester⁶  Priscilla Ivester²  Tammy C Lee² 

[1]Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA

[2]Center for Botanical Lipids and Inflammatory Disease Prevention, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA

[3]Department of Internal Medicine/Molecular Medicine, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA

[4]Department of Biochemistry, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA

[5]Center for Diabetes Research, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA

[6]Department of Urology, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA

关键词: borage + echium);    Botanical oil (BO;    Fish oil (FO);    Docosahexaenoic acid (DHA);    Eicosapentaenoic acid (EPA);    n-6 fatty acids;    n-3 fatty acids;    Polyunsaturated fatty acids (PUFAs);    Metabolic syndrome;    Diabetes;   

Others  :  1145512
DOI  :  10.1186/1476-511X-13-196

 received in 2014-08-29, accepted in 2014-12-11,  发布年份 2014

【 摘 要 】

Background

Ingestion of polyunsaturated fatty acids (PUFAs) has been proposed to influence several chronic diseases including coronary heart disease (CHD) and type-2 diabetes (T2D).There is strong evidence that omega-3 (n-3) PUFAs provide protection against CHD and biomarkers of atherosclerosis. In contrast, there is more limited and inconsistent data for T2D. Few studies have examined the impact of n-3 PUFA-containing botanical oils on T2D.

Methods

Fifty-nine subjects with early-stageT2D or metabolic syndrome participated in an 8-week, randomized, single-blind, parallel intervention study and were provided PUFA-containing oils. Individuals received either corn oil (CO), a botanical oil (BO) combination (borage [Borago officinalis L.]/echium oil [Echium plantagineum L.]) or fish oil (FO). The BO combination was enriched in alpha-linolenic, gamma-linolenic, and stearidonic acids and the FO in eicosapentaenoic and docosahexaenoic acids. Serum fatty acids and other serum lipids(triglycerides and total, HDL and LDL cholesterol), as well as markers of inflammation (leptin, and C-reactive protein) and glucose regulation (glucose and hemoglobin A1c) were assessed from fasting participants at baseline and after the intervention.

Results

Compliance was verified by expected increases in specific PUFAs in each of the three oil arms. Participants in the CO group showed no differences in serum lipids, markers of inflammation or glucose regulation between pre- and post-treatment measures. Supplementation with BO significantly lowered total and LDL cholesterol levels and FO reduced serum triglycerides, hemoglobin A1c and increased HDL-cholesterol.

Conclusion

Short-term dietary supplementation with BO and FO improved biomarkers associated with T2D/metabolic syndrome.

Trial registration

Clinicaltrial.gov NCT01145066

【 授权许可】

   
2014 Lee et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Flegal KM, Carroll MD, Ogden CL, Curtin LR: Prevalence and trends in obesity among US adults, 1999–2008. JAMA 2010, 303:235-241.
• [2]Kopelman PG: Obesity as a medical problem. Nature 2000, 404:635-643.
• [3]Kahn SE, Hull RL, Utzschneider KM: Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444:840-846.
• [4]Boden G: Obesity and free fatty acids. Endocrinol Metab Clin North Am 2008, 37:635-646.
• [5]Bang HO, Dyerberg J, Sinclair HM: The composition of the Eskimo food in north western Greenland. Am J Clin Nutr 1980, 33:2657-2661.
• [6]Kromhout D, Bosschieter EB, de Lezenne CC: The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985, 312:1205-1209.
• [7]Harris WS: n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997, 65:1645S-1654S.
• [8]Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ: Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 2002, 20:1493-1499.
• [9]Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J: Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006, 189:19-30.
• [10]Lavie CJ, Milani RV, Mehra MR, Ventura HO: Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009, 54:585-594.
• [11]Strand E, Pedersen E, Svingen G, Schartum-Hansen H, Rebnord E, Bjorndal B, Seifert R, Bohov P, Meyer K, Hiltunen J, Nordrehaug J, Nilsen D, Berge R, Nygård O: Dietary intake of n-3 long-chain polyunsaturated fatty acids and risk of myocardial infarction in coronary artery disease patients with or without diabetes mellitus: a prospective cohort study. BMC Medicine 2013, 11:216. BioMed Central Full Text
• [12]Hartweg J, Farmer AJ, Perera R, Holman RR, Neil HAW: Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia 2007, 50:1593-1602.
• [13]Stone NJ: Fish consumption, fish oil, lipids, and coronary heart disease. Circulation 1996, 94:2337-2340.
• [14]Saravanan P, Davidson NC, Schmidt EB, Calder PC: Cardiovascular effects of marine omega-3 fatty acids. Lancet 2010, 376:540-550.
• [15]Kaushik M, Mozaffarian D, Spiegelman D, Manson JE, Willett WC, Hu FB: Long-chain omega-3 fatty acids, fish intake, and the risk of type 2 diabetes mellitus. Am J Clin Nutr 2009, 90:613-620.
• [16]Djousse L, Gaziano JM, Buring JE, Lee IM: Dietary omega-3 fatty acids and fish consumption and risk of type 2 diabetes. Am J Clin Nutr 2011, 93:143-150.
• [17]Hartweg J, Farmer AJ, Holman RR, Neil A: Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes. Curr Opin Lipidol 2009, 20:30-38.
• [18]Jeppesen C, Schiller K, Schulze MB: Omega-3 and omega-6 fatty acids and type 2 diabetes. Curr Diab Rep 2013, 13:279-288.
• [19]Calder PC: Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale. Biochimie 2009, 91:791-795.
• [20]Calder PC: Dietary modification of inflammation with lipids. Proc NutrSoc 2002, 61:345-358.
• [21]Serhan CN, Gotlinger K, Hong S, Arita M: Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat 2004, 73:155-172.
• [22]Belch JJ, Hill A: Evening primrose oil and borage oil in rheumatologic conditions. Am J Clin Nutr 2000, 71:352S-356S.
• [23]Zurier RB, Rossetti RG, Jacobson EW, DeMarco DM, Liu NY, Temming JE, White BM, Laposata M: gamma-Linolenic acid treatment of rheumatoid arthritis. A randomized, placebo-controlled trial. Arthritis Rheum 1996, 39:1808-1817.
• [24]Johnson MM, Swan DD, Surette ME, Stegner J, Chilton T, Fonteh AN, Chilton FH: Dietary supplementation with gamma-linolenic acid alters fatty acid content and eicosanoid production in healthy humans. J Nutr 1997, 127:1435-1444.
• [25]Brzeski M, Madhok R, Capell HA: Evening primrose oil in patients with rheumatoid arthritis and side-effects of non-steroidal anti-inflammatory drugs. Br J Rheumatol 1991, 30:370-372.
• [26]Keen H, Payan J, Allawi J, Walker J, Jamal GA, Weir AI, Henderson LM, Bissessar EA, Watkins PJ, Sampson M, Gale E, Scarpello J, Boddie H, Hardy K, Thomas P, Misra P, Halonen J, The gamma-Linolenic Acid Multicenter Trial Group: Treatment of diabetic neuropathy with gamma-linolenic acid. Diabetes Care 1993, 16:8-15.
• [27]Arm JP, Boyce JA, Wang L, Chhay H, Zahid M, Patil V, Govindarajulu U, Ivester P, Weaver KL, Sergeant S, Israel E, Chilton FH: Impact of botanical oils on polyunsaturated fatty acid metabolism and leukotriene generation in mild asthmatics. Lipids Health Dis 2013, 12:141. BioMed Central Full Text
• [28]Kavanagh K, Flynn DM, Jenkins KA, Wilson MD, Chilton FH: Stearidonic and gamma-linolenic acids in echium oil improves glucose disposal in insulin resistant monkeys. Prostaglandins Leukot Essent Fatty Acids 2013, 89:39-45.
• [29]American Diabetes Association: Standards of medical care in diabetes--2013. Diabetes Care 2013, 36(Suppl 1):S11-66.
• [30]Mugabo Y, Li L, Renier G: The connection between C-reactive protein (CRP) and diabetic vasculopathy. Focus on preclinical findings. Curr Diabetes Rev 2010, 6:27-34.
• [31]Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T: High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care 2006, 29:329-333.
• [32]Nettleton JA, Katz R: n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: A review. J Am Diet Assoc 2005, 105:428-440.
• [33]Wang L, Folsom A, Zheng Z, Pankow J, Eckfeldt J: Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr 2003, 78:91-98.
• [34]Vessby B, Aro A, Skarfors E, Berglund L, Salminen I, Lithell H: The risk to develop NIDDM is related to the fatty acid composition of the serum cholesterol esters. Diabetes 1994, 43:1353-1357.
• [35]Hu FB, van Dam RM, Liu S: Diet and risk of Type II diabetes: the role of types of fat and carbohydrate. Diabetologia 2001, 44:805-817.
• [36]Virtanen JK, Mursu J, Voutilainen S, Uusitupa M, Tuomainen TP: Serum omega-3 polyunsaturated fatty acids and risk of incident type 2 diabetes in men: the Kuopio Ischemic Heart Disease Risk Factor study. Diabetes Care 2014, 37:189-196.
• [37]Jafari T, Fallah AA, Azadbakht L: Role of dietary n-3 polyunsaturated fatty acids in type 2 diabetes: a review of epidemiological and clinical studies. Maturitas 2013, 74:303-308.
• [38]Blasbalg TL, Hibbeln JR, Ramsden CE, Majchrzak SF, Rawlings RR: Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. Am J Clin Nutr 2011, 93:950-962.
• [39]Surette ME, Edens M, Chilton FH, Tramposch KM: Dietary echium oil increases plasma and neutrophil long-chain (n-3) fatty acids and lowers serum triacylglycerols in hypertriglyceridemic humans. J Nutr 2004, 134:1406-1411.
• [40]Banz WJ, Davis JE, Clough RW, Cheatwood JL: Stearidonic acid: is there a role in the prevention and management of type 2 diabetes mellitus? J Nutr 2012, 142:635S-640S.
• [41]Taylor CG, Noto AD, Stringer DM, Froese S, Malcolmson L: Dietary milled flaxseed and flaxseed oil improve N-3 fatty acid status and do not affect glycemic control in individuals with well-controlled type 2 diabetes. J Am Coll Nutr 2010, 29:72-80.
• [42]Komatsu W, Ishihara K, Murata M, Saito H, Shinohara K: Docosahexaenoic acid suppresses nitric oxide production and inducible nitric oxide synthase expression in interferon-gamma plus lipopolysaccharide-stimulated murine macrophages by inhibiting the oxidative stress. Free Radic Biol Med 2003, 34:1006-1016.
• [43]Spencer L, Mann C, Metcalfe M, Webb M, Pollard C, Spencer D, Berry D, Steward W, Dennison A: The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential. Eur J Cancer 2009, 45:2077-2086.
• [44]Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL: Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002, 196:1025-1037.
• [45]Ariel A, Serhan CN: Resolvins and protectins in the termination program of acute inflammation. Trends Immunol 2007, 28:176-183.
• [46]Spector AA: Essentiality of fatty acids. Lipids 1999, 34(Suppl):S1-3.
• [47]Calder PC: The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. Mol Nutr Food Res 2012, 56:1073-1080.
• [48]Smith WL: Cyclooxygenases, peroxide tone and the allure of fish oil. Curr Opin Cell Biol 2005, 17:174-182.
• [49]Balvers MG, Verhoeckx KC, Bijlsma S, Rubingh CM, Meijerink J, Wortelboer HM, Witkamp RF: Fish oil and inflammatory status alter the n-3 to n-6 balance of the endocannabinoid and oxylipin metabolomes in mouse plasma and tissues. Metabolomics 2012, 8:1130-1147.
• [50]Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C, Heart NHLBIA: Definition of metabolic syndrome - Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arteriosclerosis Thromb Vascul Biol 2004, 24:E13-E18.
• [51]Metcalfe LD, Schmitz AA, Pelka JR: Rapid Preparation of Fatty Acid Esters from Lipids for Gas Chromatographic Analysis. Anal Chem 1966, 38:514-515.
• [52]Weaver KL, Ivester P, Seeds M, Case LD, Arm JP, Chilton FH: Effect of dietary fatty acids on inflammatory gene expression in healthy humans. J Biol Chem 2009, 284:15400-15407.